Chicago Biomedical Consortium

presents

CBC Accelerator Network:

Presentations of the CBC Accelerator Award
Letters of Intent (LOIs), Round 2, 2018

PART II
Thursday, August 16, 2018

4:00 - 7:00 PM

Northwestern Memorial Hospital
Prentice Women’s Hospital
Room L South
250 East Superior Street
Chicago, IL 60611

The CBC gratefully acknowledges support from the Searle Funds
at The Chicago Community Trust
CBC MISSION

The mission of the Chicago Biomedical Consortium (CBC) is to stimulate collaboration among scientists at Northwestern University, The University of Chicago, the University of Illinois at Chicago and others to accelerate discovery that will transform biomedical research and improve the health of humankind. The CBC will:

• Stimulate research and education that bridge institutional boundaries,
• Enable collaborative and interdisciplinary research that is beyond the range of a single institution,
• Mentor and develop a strong cadre of biomedical leaders, researchers, and entrepreneurs in Chicago,
• Enhance and promote the development of the biomedical ecosystem in Chicago,
• Facilitate development of therapeutics that will, over the long term, improve the health of citizens of Chicago and beyond.

CBC LEADERSHIP

Luisa DiPietro, DDS, PhD, Scientific Director, University of Illinois at Chicago
T: 312-355-0432, E: Ldipiet@uic.edu

Lucy Godley, MD, PhD, Scientific Director, The University of Chicago
T: 773-702-4140, E: lgodley@medicine.bsd.uchicago.edu

Richard Morimoto, PhD, Scientific Director, Northwestern University
T: 847-491-3340, E: r-morimoto@northwestern.edu

Jim Audia, PhD, Executive Director, Northwestern University
T: 847-467-6745, E: jeaudia1@northwestern.edu

CBC STAFF

Karen Snapp, DDS, PhD, Senior Associate Director, Northwestern University
T: 847-467-0633, E: ksnapp@northwestern.edu

Nancy Tyrrell, Associate Director for Translational Activities, Northwestern University
T: 847-467-1094, E: nancy.tyrrell@northwestern.edu

Kimberly Corn, Associate Director, Business Operations and Finance, Northwestern University
T: 847-467-0357, E: k-corn@northwestern.edu

Jola Glotzer, MD, Communications Director, The University of Chicago
T: 773-834-5132, E: jolaglotzer@uchicago.edu

Corinna Kitcharoen, MBA, Program Coordinator, University of Illinois at Chicago
T: 312-996-1311, E: cktitch1@uic.edu

www.chicagobiomedicalconsortium.org
4:00 PM  PARTICIPANTS' SELF-INTRODUCTION
Each person introduces themselves and their institution/affiliation.

4:10 PM  INTRODUCTORY REMARKS
Overview of the CBC Accelerator Award program; status of the Round 1 and Round 2 application cycles.
Jim Audia, CBC Executive Director and Nancy Tyrrell, CBC Associate Director for Translational Activities

PRESENTATIONS OF LETTERS OF INTENT (LOIs) FOR THE CBC ACCELERATOR AWARD PROGRAM

4:15 PM  Steven Ackerman and Vadim Gaponenko (UIC)
Novel CCR3 Peptide Biased Antagonist for Therapy of Eosinophilic Asthma

4:35 PM  Richard Kraig (UChicago)
Verification of In Vivo Distribution of IGF-1 via Nose-to-Brain Administration

4:55 PM  Leslie Fung and Michael Johnson (UIC)
Establish Animal Efficacy Proof of Concept for Highly Active Antimicrobial Leads

5:15 PM  Brian Kay (UIC)
A Platform Technology for Discovering Two-Site Affinity Reagents

5:35 PM  Terry Vanden Hoek (UIC)
Novel PHLPP Peptide for Asystole/PEA Resuscitation

5:55 PM  CONCLUDING REMARKS
Jim Audia and Nancy Tyrrell

Part II  NETWORKING  3rd Floor, Harris Family Atrium

6:00 PM  NETWORKING RECEPTION
7:00 PM  ADJOURN
The Accelerator Award program supports translational research and provide university researchers with “early commercial guidance.” Accelerator Awards are to be used to support the initial, and therefore highest risk, stage of commercially-directed research focused on the development of a therapeutic or an associated biomarker or diagnostic. The program encourages interactions between academic researchers and industry/pharmaceutical experts early in the development of projects and provides advice to award recipients in setting and progressing toward commercialization milestones. Award recipients will be mentored by faculty, industry experts, tech transfer officers and CBC personnel. Accelerator awardees will provide project updates at CBCAN meetings.

Letters of Intent (LOIs) to submit translational research projects are required for initial triage by the CBC Leadership. Selected LOIs are presented at a CBCAN meeting and evaluated by the Accelerator Review Board (ARB). The finalists are invited to submit full proposals, which must discuss commercial potential, milestones and deliverables, and incorporate the ARB feedback from the CBCAN. Accelerator Awards are for $100,000 for one year.

Awarded projects that have met proposed milestones during the first year may be invited to apply for $150,000 for one additional year.

ACCELERATOR AWARD DETAILS AND ELIGIBILITY:

- Applicants must be tenured or tenure-track faculty with research programs at Northwestern University, The University of Chicago, and/or University of Illinois at Chicago. Faculty with full time appointments on the clinical track at each of the institutions are also eligible to apply. Applicants must have their own designated laboratory space. Individuals who carry faculty appointments with parenthetical rank, are not eligible for tenure, and do not have their own laboratory space are not eligible to apply.

- Although collaborative proposals are encouraged there is no specific requirement for cross-institutional collaboration.

- Applicants may have created a company to pursue translation of their innovation, but there is no expectation or requirement for so doing. The CBC encourages applications prior to or without company formation.

- Multiple applications can be submitted from each institution.

- There is no expectation that Accelerator Awards will be distributed evenly among the CBC institutions.

- Proposals should show both innovation and scientific merit.

- The project should be focused on the development of a therapeutic or associated diagnostic or biomarker, built around a compelling hypothesis and focus on gathering data that advances the hypothesis and discharges key translational risks.

- Research teams should not already be funded for the same (or closely related) specific aims and/or milestones.

- Research projects described in Accelerator applications cannot be under review at other funding institutions/agencies to support the same (or closely related) specific aims and/or milestones.

- A PI may participate in only one application per round.

- Ongoing and active participation in the CBCAN program is a requirement for Accelerator Award recipients.

ROUND 3 APPLICATION DATES: JANUARY 14-18, 2019
CBCAN Meeting
Thursday, November 15, 2018
TOPIC: Fireside Chat with Jigar RAYTHATHA, President and Chief Executive Officer, Constellation Pharmaceuticals
TIME: 4:00 – 7:00 PM
LOCATION: Chicago downtown, TBA

RFA: CBC Catalyst Award program
One-time incentive awards (up to $250,000) focused on fundamental biological/biomedical research with transformative potential, eligible to teams with co-Principal Investigators from at least two of the CBC institutions.
Round 26 (Fall 2018) Catalyst application submissions open August 20 and close at 5:00 PM on August 24, 2018.

16th CBC Annual Symposium:
A New Age of Structural Biology: Structure Meets Dynamics
Wednesday, October 3, 2018
LOCATION: Northwestern Memorial Hospital
Feinberg Pavilion, Rooms A – D
251 East Huron Street, Chicago, IL 60611

This all-day event is organized by Alfonso Mondragón (NU-Chairman), Tony Kossiakoff (UChicago), Arnon Lavie (UIC) and Valerie Tokars (NU). The meeting will also include a poster session. The event is free of charge, but pre-registration is required.
Stellar speaker lineup: Jingyi FEI, UChicago; André HOELZ, Caltech; Janet SMITH, University of Michigan; Reza VAFABAKHSH, NU; Eric XU, Van Andel Institute and Xiaojing YANG, UIC.

Check out our symposium flyer on the back cover of this program!
Online registration and abstract submission portals are already open.
DEADLINE: Friday, September 7, 2018.

CBC Spring Course:
Preclinical Safety Assessment and Mitigation Strategies in Drug Discovery
DATE: April 2019, TBA (One and a Half Days Course)
LOCATION: Chicago downtown, TBA
INSTRUCTOR: Bryan H. NORMAN, Independent Consultant/Instructor (retired from Eli Lilly and Company)

This course will begin with an assessment of the finish line for preclinical drug hunters—the successful filing of an Investigational New Drug (IND) application to regulatory agencies, such as the FDA or EMA. Importantly, the course will focus on the toxicology-chemistry partnership in discovery safety assessment. It will explore mitigation strategies and will include both the strategic concepts and study designs used in preclinical safety assessment. It will also describe some of the common pitfalls in toxicological data interpretation and how to best use the data to inform a lead optimization strategy and ultimate clinical study design. The course will cover many of the most common risks and modern mitigation strategies to help drug discovery teams navigate an optimization effort geared to delivering safe and well tolerated potential new therapies in the shortest time possible.

www.chicagobiomedicalconsortium.org
Chicago Biomedical Consortium
16th Annual Symposium

A New Age of Structural Biology: Structure Meets Dynamics

October 3, 2018
9:00 AM - 6:00 PM

Northwestern Memorial Hospital
Feinberg Conference Center, Rooms A – D
251 East Huron Street
Chicago, IL 60611

Jingyi FEI
The University of Chicago
Two-step Binding Kinetics of tRNA Ligand by T-box Riboswitch

Reza VAFABAKHSH
Northwestern University
Information Processing at the Plasma Membrane

André HOELZ
Caltech
The Structure of the Nuclear Pore Complex

Eric XU
Van Andel Institute
Structural Biology of GPCR Signaling Complexes

Janet SMITH
University of Michigan
APOBEC3H-RNA in the Molecular Arms Race Against HIV

Xiaojing YANG
University of Illinois at Chicago
Observing Protein Structure Dynamics at Atomic Resolution

Registration and poster abstract submission deadline is noon, Friday, September 7, 2018.
For program and registration details, go to:

www.chicagobiomedicalconsortium.org